Kamada (NASDAQ:KMDA) announced its earnings results on Tuesday. The biotechnology company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.08, Morningstar.com reports. Kamada had a net margin of 19.48% and a return on equity of 22.74%. The business had revenue of $26.80 million during the quarter, compared to the consensus estimate of $22.87 million. Kamada updated its FY 2019 guidance to EPS.
Shares of KMDA traded up $0.02 during mid-day trading on Wednesday, reaching $5.77. 17,476 shares of the company’s stock were exchanged, compared to its average volume of 152,947. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.70 and a quick ratio of 3.46. Kamada has a 52-week low of $4.55 and a 52-week high of $6.70. The stock has a market cap of $227.08 million, a price-to-earnings ratio of 10.49 and a beta of 1.15.
Several equities research analysts have recently weighed in on KMDA shares. Zacks Investment Research upgraded shares of Kamada from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research note on Thursday, February 14th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Kamada in a research note on Thursday, February 14th.
WARNING: This piece was posted by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://weekherald.com/2019/05/15/kamada-kmda-posts-quarterly-earnings-results-beats-expectations-by-0-08-eps.html.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
See Also: Are analyst ratings accurate?
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.